Global Advanced Genomics Market 2025 – 2034

Reports Description

As per the Advanced Genomics Market analysis conducted by the CMI team, the global advanced genomics market is expected to record a CAGR of 16.21% from 2025 to 2034. In 2025, the market size was USD 48.31 Billion. by 2034, the valuation is anticipated to reach USD 186.70 Billion.

Overview

The growing incidences of inherited cancers are anticipated to drive the advanced genomics market during the forecast period. The noticeable understanding on the part of the human genome has translated into the usage of several gene therapies to treat cancers through modern gene editing techniques like CRISPR-Cas gene technology. Along these lines, in September 2022, researchers at the University of California floated applications of precision genome editing agents to manage inherited retinal diseases (IRDs).

Developing high throughput sequencing technologies like microarrays and Next-generation Sequencing (NGS) has resulted in the generation of massive quantities of genomic data.

At the same time, speedy accumulation of the data from Electronic Health Records (EHRs) and DNA sequencing does pose substantial challenges, thereby generating opportunities for extraction of clinically or biologically relevant information. Genome-wide association studies (GWAS) and phenome-wide association studies (PheWAS) are aiding researchers in studying correlations between phenotype and genotype.

The key players are working on an extensive note toward expansions, collaborations, big capital investments, and acquisitions to conduct advanced research in order to comprehend rare diseases and help in drug discovery. For example – pacBio worked in collaboration with the Genomics England Society to utilize its technology for detecting genetic variation in the rare disorders that go unnoticed in the first attempt and are unexplained. The Around 100,000 genomes project belonging to England aims to discover potential clinical and operational advantages of long-read sequencing to identify mutations linked with rare diseases.

Key Trends & Drivers

• Rise in Prevalence of Cancer and Genetic Disorders

Research states that around 450 million individuals are affected by rare genetic disorders at some point in their life span. As per RareX’s Power of Being Counted report, the world witnessed 7K-8K accepted rare diseases a decade ago and the number has been rising since then. It further states that as of June 2022, this figure had reached 10,867.

As per the International Agency for Research on Cancer’s (IARC’s) report published in 2022, the world witnessed the registration of 20 million new cases of cancer at the global level followed by 9.7 fatalities in 2021. The fast growing cancer burden does reflect on both population explosion and aging, along with alterations in exposure of individuals to various risk factors, many of which are linked with socioeconomic development.

The growing incidences of cancer and genetic disorders across the globe do necessitate advanced genomics for diagnosing, treating, and prevention on their part.

• Need for Personalized Medicine, Drug Discovery, and Diagnostics

Advanced genomics plays a crucial role in customizing the treatment plans on the basis of the genetic parlance of an individual, thereby resulting in better targeted therapies. It also plays an indispensable role in the identification of potential drug targets, thereby accelerating the process of drug development and cutting down on errors in the clinical trials. Customization helps in expediting the treatment of several disease areas such as infectious diseases apart from cancer and rare ones.

Key Threats

Dearth of Skilled Technicians and Inconsistency regarding Regulatory Approvals

Many emerging economies tend to have fewertechnicians or ones who lack the skills needed to use sophisticated sequencers. Also, the higher cost of instruments is reducing market expansion.

Additionally, there are challenges associated with secured storage pertaining to huge volumes of generated data. It is not possible for various biopharmaceutical companies and research institutes to extend financial support to large-scale genome projects.

The non-uniformity of regulations is another factor restraining the advanced genomics market. For instance, every economy has its own regulatory authority that applies diverse guidelines and regulations to manufacturers. To ascertain products’ safety, the CDC, the U.S. FDA, and various other regulatory bodies have put their guidelines into practice.

Opportunities

Several emerging technologies are poised to provide lucrative opportunities to the advanced genomics market. Spatial multi-omics does integrate transcriptomic, genomic, metabolomic, and proteomic data with spatial information, mentioning how the molecular processes differ across organs and tissues.

Liquid biopsies detect circulation of tumor DNA, facilitating non-invasive cancer monitoring as well as early detection. The ongoing research conducted on an extensive scale aims toward expansion of this approach to the other conditions, thereby revolutionizing the diagnostic practices.

Epigenome editing does move beyond the modification of DNA sequence for altering regulation of genes through the targeted alterations to DNA methylation and chromatin structure, thereby offering novel therapeutic possibilities for the conditions implying dysregulated gene expression.

What’s trending in the Advanced Genomics Market?

The huge quantities of data generated need AI and advanced analytics for interpreting and extracting meaningful insights. ML and AI are being used for accelerating data analysis for drug discovery and disease diagnostics. Integrating big data and AI is one of the key trends shaping the advanced genomics market.

CRISPR-Cas9 and the other gene-editing tools are refurbishing the field of advanced genomics, thereby offering probabilities to correct genetic defects and develop novel therapies. Such technologies are unleashing the possibilities to treat a broad spectrum of diseases.

These days advanced genomics is used for developing medications and vaccines based on the genetic profile of the patient.

Category Wise Insights

By Offering

• Products

Advanced genomics covers a spectrum of products inclusive of DNA sequencing technologies such as single-molecule real-time (SMRT) and nanopore sequencing, gene editing tools such as CRISPR and zinc finger nucleases (ZFN), genetic screening solutions, RNAi libraries, various socialized kits for NGS. Such tools are used in several areas such as diagnostics, drug discovery, and farming. The specialized kits and assays include NGS panels (personalized panels of DNA sequences meant to target sequencing of specific regions or genes), exome capture kits (kits meant to capture and sequence protein-coding regions of the genome), DNA/RNA extraction kits (kits meant to isolate and purify RNA and DNA from several types of samples), and qPCR and PCR reagents and kits (tools to amplify and quantify specific RNA or DNA sequences).

• Services

The services encompassing the global advanced genomics market include whole genome and exome sequencing (in-depth analysis of the patient’s whole genome (entire DNA) or merely the protein-coding regions (exome) for identifying the genetic variations linked with rare/undiagnosed conditions), hereditary cancer screening (assessment of the risk of inherited cancers such as ovarian, breast, colorectal, and likewise), newborn and prenatal screening, and cardiogenomics and neurogenomics (specialized genetic testing for neurological and cardiovascular conditions).

The other services include pharmacogenomics (personalized drug response testing meant for optimizing efficacy of treatment on the basis of the genetic makeup of an individual), targeted therapy selection (identification of genetic markers to guide treatment decisions for several types of cancers and other ailments), and predictive genetic testing (assessment of an individual’s risk of contracting certain diseases in the near future).

By Technology

• Sequencing

Sequencing technologies, especially Next-Generation Sequencing (NGS), facilitate high-throughput, affordable analysis of RNA and DNA, thereby resulting in advancements in personalized medicine, disease diagnosis, and drug discovery. NGS is important with regard to diagnosing genetic disorders, identifyingmutations causing diseases, and enhancing the speed and precision of diagnosis, particularly for rare diseases. Also, the ongoing trend of outsourcing the NGS services has created various opportunities for the industrial leaders to offer cost-effective and advanced sequencing services, thereby boosting the market.

• PCR

PCR, or polymerase chain reaction, facilitates amplification of specific DNA sequences. It is crucial for several genomic analyses inclusive of genetic testing, gene expression studies, and detection of pathogens, thereby accelerating the demand for advanced genomics products and services.

PCR allows for creating billions of copies of specific DNA sequences in a comparatively shorter time span, even for a petite initial sample.

• Gene Editing

Gene editing helps in developing personalized medicine and new therapies and improving crop production, thereby resulting in increased commercialization and research. Improved crops are capable of contributing to food security by enabling a rise in food production in a much more sustainable manner.

Gene editing is also used for creating novel lines for research, both for applied biotechnology and basic research.

• Flow Cytometry

Flow Cytometry enables cells’ high-throughput analysis, thereby fostering identification of exclusive biomarkers and extending support to personalized medicine. The ability to analyze multiple cellular characteristics along with precision and speed does make it a vital tool regarding advanced genomics diagnostics and research. It also implies harnessing the power of the immune system for fighting diseases such as cancer.

• Microarrays

Microarrays enable drug discovery, disease diagnosis, and customized medicine. They let researchers study gene expression, identify variations in genetics, and discover the disease markers, thereby resulting in better understanding of biological processes with innovation in several applications.

Microarrays let researchers analyze hordes of RNA or DNA sequences simultaneously on a single chip, notably increasing the efficiency and speed of genomic studies. They aid in the classification of cancer subtypes, guiding the strategies of treatment, and facilitating personalized medicine approaches.

• In Situ Hybridization

In situ hybridization (ISH) noticeably contributes to the expansion of the advanced genomics market by facilitating localization and detection of specific RNA or DNA sequences within the tissues and cells. The technique is important for understanding the gene expression patterns, thereby identifying genetic abnormalities and studying the cells’ functional state. These are crucial aspects of the advanced genomics research as well as diagnostics.

By Application

• Diagnostics

Advanced diagnostics play an important role in the expansion of the advanced genomics market by facilitating precision medicine, thereby enhancing treatment outcomes and driving research and development activities. Genomic information obtained via diagnostics is vital in order to identify potential drug targets. Diagnostics aid in identifying biomarkers that could be used for monitoring disease progression, predicting treatment response, and personalizing treatment plans.

• Drug Discovery and Development

Drug discovery and development focus on personalized medicine, which would, in turn, be driven by genomics research. It also necessitates the advanced tools to identify drug targets, wherein it predicts the response of patients and optimizes clinical trials. This thus creates opportunities for the companies that specialize in bioinformatics, genomics technologies, and precision medicine.

• Precision Medicine

Precision medicine tailors healthcare to the genetic profiles individually. This, in turn, drives the demand for data analysis tools and genomic technologies. Such an approach makes use of genomic information for developing personalized and more effective treatments, thereby resulting in increased research & development activities in therapies, preventive measures, and diagnostics based on genomics.

• Agriculture

Advanced genomics is witnessing an upsurge in the farming sector, basically driven by the requirement for efficient and sustainable food production. Genomics herein makes use of genetic information for improving livestock and crop yields, improving resistance against diseases, and coming up with climate-resilient varieties. Pest-resistant and disease-resistant crops that are developed through genomics could cut down on the need for chemical interventions.

By End-user

• Hospitals & Clinics

Hospitals & clinics are the key users of advanced genomics. They use it for personalized medicine, diagnostics, and treatment optimization.

Advanced genomics is increasingly getting integrated into routine clinical practice with applications in oncology, prenatal screening, and pharmacogenomics. Clinical settings make way for valuable patient and data samples for research, thereby accelerating the development of novel genomic technologies as well as applications.

• Research Centers

Research centers conduct fundamental research, conduct training of the workforce, and generate data fueling the development of newfangled therapies, diagnostics, and personalized medicine approaches. They develop as well as refine advanced genomic technologies such as NGS, CRISPR, and bioinformatics.

Research centers do generate a large quantity of genomic data that is crucial to understanding disease mechanisms, identifying biomarkers, and developing new therapies.

• Pharmaceutical and Biotechnology Companies

Pharmaceutical and biotechnology companies contribute to expanding the advanced genomics market by driving the innovation with respect to diagnostics, drug discovery, and personalized medicine. They thus leverage genomics for developing targeted therapies, accelerating the development of new treatments, and enhancing patient outcomes.

How is Next-generation Sequencing effective in Advanced Genomics Market?

Next-generation sequencing (NGS) facilitates quicker, more comprehensive, and more cost-effective analysis of RNA and DNA. The technology lets researchers analyze huge quantities of generic information, thereby resulting in breakthroughs with respect to medicine, disease diagnostics, and drug discovery. The increasing throughput and declining cost of NGS are accelerating its adoption across several applications. For instance, NGS provides deep insights into the genomic structure, epigenetic modifications, and gene expressions, thereby helping researchers understand the mechanisms of the diseases and identify drug targets.

Report Scope

Regional Perspective

The advanced genomics market is classified into North America, Europe, Asia Pacific, and LAMEA.

• North America

North America held the largest market share (~40%) in the year 2023. This could be attributed to support extended by research institutes as well as pharmaceutical giants. The present scenario in the U.S. is such that genomics is among the integral parts of any disease-related research and drug discovery owing to the positive impact of genetic expressions on human health. In January 2022, Illumina, Inc. entered into collaboration with Nashville Biosciences, LLC (part of Vanderbilt University Medical Center at Tennessee) for developing drugs by utilizing genomics and establishing clinico-genomic resources.

• Asia Pacific

Asia Pacific is expected to grow at the fastest rate in the global advanced genomics market. This is due to the rise in demand for advanced genomics applications in diagnostics along with new therapeutic drugs for fighting the rising incidences of diseases herein. Various major human genome sequencing projects are being executed. Under genome Asia 100K, the Asian genomes get sequenced followed by analysis, which can help in accelerating population-specific medical advances.

• Europe

In the Europe, genomic information is increasingly used for tailoring treatments to the individual patients, thereby resulting in more targeted and effective therapies. Innovation with respect to genomic research as well as technologies such as bioinformatics and high-throughput sequencing are making genomic analysis more efficient and accessible.

• LAMEA

Growth of the advanced genomics market in LAMEA is driven by a rise in awareness of genetic testing and a growing number of research initiatives. This growth is evident in the form of the adoption of NGS for clinical research and diagnostics, along with the expansion of applications of advanced genomics in agriculture, healthcare, and biodiversity conservation.

Key Developments

The advanced genomics market is witnessing a robust organic and inorganic expansion. Some of the key developments include –

• In November 2023, Fabric genomics announced that it had entered into collaboration with Oxford nanopore Technologies in order to deploy CLIA/CAP labs in neonatal and pediatric ICUs. The labs would be using Oxford Nanopore’s platforms for studying genetic disorders in the infants.

• In February 2023, Illumina, Inc. announced a collaboration with the African Centre of Excellence for Genomics of Infectious Diseases in order to establish a training institute for increasing genomic capabilities in the African region.

• In January 2023, SOPHiA GENETICS entered into a collaboration with the Memorial Sloan Kettering Cancer Center (MSK) in order to offer clinicians and researchers solutions for expanding testing and analytical capabilities.

• In January 2023, Agilent Technologies, Inc. announced that it had completed the acquisition of Avida Biomed (a company known for developing target enrichment workflows for clinical researchers using NGS methods for studying cancers).

Leading Players

The advanced genomics market is highly competitive, with a large number of service providers globally. Some of the key players in the market include:

• Illumina
• Thermo Fisher Scientific
• Danaher Corporation
• Agilent Technologies Inc.
• QIAGEN
• Oxford Nanopore Technologies
• Pacific Biosciences of California Inc.
• BGI Genomics
• Myriad Genetics Inc.
• Eurofins Scientific
• Hoffmann-LA Roche AG
• Laboratory Corporation of America Holdings
• Revvity
• Luminex Corporation
• Bio Rad Laboratories, Inc.
• Others

These firms apply a plethora of strategies to enter the market, including innovations, mergers and acquisitions, and collaboration. The advanced genomics market is shaped by the presence of diversified players that compete based on product innovation, vertical integration, and cost efficiency.

The Advanced Genomics Market is segmented as follows:

By Offering

• Products
• Services

By Technology

• Sequencing
• PCR
• Gene Editing
• Flow Cytometry
• Microarrays
• In Situ Hybridization

By Application

• Diagnostics
• Drug Discovery and Development
• Precision Medicine
• Agriculture

By End-user

• Hospitals and Clinics
• Research Centers
• Pharmaceutical and Biotechnology Companies

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America